HMPL-813 in Treating Patients With Glioblastoma

Summary

This is an open-label study, to evaluated epitinib, which is a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), to treat glioblastoma patients with EGFR gene amplification. As epitinib could cross blood-brain barrier (BBB), inhibition of EGFR may provide a novel mechanism in treating glioblastoma.

Timeline

Start

2018-01-26

Primary completion

2020-06-30

Completion

2020-08-31

Drugs

Indications